ArticleThe oncologist2025
Characteristics and outcomes of patients with pregnancy-associated colorectal cancer.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPregnancy-associated colorectal cancer (PACRC) is a rare condition with limited existing research. Its occurrence during pregnancy introduces unique physiological complexities, making diagnosis and treatment particularly challenging for clinicians. This study aimed to characterize PACRC by examining its clinical features, obstetric management approaches, therapeutic strategies, and maternal-fetal survival outcomes.
methodsA comprehensive literature review was conducted using studies published from January 2016 to March 2024. Cox proportional hazards regression was used to identify prognostic factors affecting overall survival (OS). Chi-square tests were used to assess differences in fetal mortality and preterm birth rates across exposure groups.
resultsA total of 121 PACRC patients were included, and most were diagnosed in late pregnancy or postpartum. PACRC was more frequently located in the left colon and rectum, typically diagnosed at advanced stages. Most tumors were moderately or poorly differentiated adenocarcinomas. The 1-year and 2-year maternal survival rates were 69.90% and 58.60%, respectively. Prognosis was more favorable when the tumor is in the rectum rather than the colon. Surgical intervention and chemotherapy, particularly when initiated during pregnancy, were associated with significantly improved outcomes compared to postpartum therapy (HR = 0.36; 95% CI: 0.16-0.84; P = .02). Fetal mortality was not directly associated with prenatal diagnostic or therapeutic procedures, although iatrogenic pregnancy termination may contribute to fetal risk.
conclusionsPACRC, characterized by its subtle presentation, requires vigilant clinical monitoring and prompt intervention, with consideration of gestational age, histological type, and tumor stage. Our findings suggest that early surgical intervention and chemotherapy during pregnancy may offer greater survival benefits than treatment initiated only after pregnancy termination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.